Strategic Science & Technologies, LLC (SST) recently entered into a worldwide licensing agreement for a lead program with a well-known consumer health company for one of its late-stage OTC products.

Strategic Science & Technologies, LLC (SST) partners with pharmaceutical and life science companies that currently have or are developing products that can benefit from KNOSIS, its innovative technology, which offers the ability to deliver pharmaceutical agents transdermally. The proprietary platform technology not only makes medications faster acting, it also lowers toxicity associated with taking them orally due to much lower systemic dosage and no gastrointestinal (GI) side effects. Partnering with SST, and licensing its advanced topical technology also helps companies increase existing sales and extend expiring patents. With both KNOSIS, and the Company's comprehensive and unique intellectual property portfolio at their ready, partners have a cost-effective method of creating and marketing transdermally delivered drugs.